- Home
- ELVN vs NAVI Comparison
ELVN vs NAVI Comparison
Compare ELVN & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- NAVI
- Stock Information
- Founded
- ELVN 2016
- NAVI 1973
- Country
- ELVN United States
- NAVI United States
- Employees
- ELVN N/A
- NAVI N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- NAVI Investment Bankers/Brokers/Service
- Sector
- ELVN Health Care
- NAVI Finance
- Exchange
- ELVN Nasdaq
- NAVI Nasdaq
- Market Cap
- ELVN 1.2B
- NAVI 1.3B
- IPO Year
- ELVN 2020
- NAVI N/A
- Fundamental
- Price
- ELVN $20.22
- NAVI $13.49
- Analyst Decision
- ELVN Strong Buy
- NAVI Hold
- Analyst Count
- ELVN 5
- NAVI 8
- Target Price
- ELVN $41.20
- NAVI $14.19
- AVG Volume (30 Days)
- ELVN 335.0K
- NAVI 922.4K
- Earning Date
- ELVN 08-13-2025
- NAVI 07-30-2025
- Dividend Yield
- ELVN N/A
- NAVI 4.92%
- EPS Growth
- ELVN N/A
- NAVI N/A
- EPS
- ELVN N/A
- NAVI 0.31
- Revenue
- ELVN N/A
- NAVI $584,000,000.00
- Revenue This Year
- ELVN N/A
- NAVI N/A
- Revenue Next Year
- ELVN N/A
- NAVI $0.47
- P/E Ratio
- ELVN N/A
- NAVI $42.15
- Revenue Growth
- ELVN N/A
- NAVI N/A
- 52 Week Low
- ELVN $13.30
- NAVI $10.53
- 52 Week High
- ELVN $30.03
- NAVI $16.97
- Technical
- Relative Strength Index (RSI)
- ELVN 49.43
- NAVI 48.28
- Support Level
- ELVN $19.30
- NAVI $12.74
- Resistance Level
- ELVN $20.28
- NAVI $13.13
- Average True Range (ATR)
- ELVN 1.19
- NAVI 0.31
- MACD
- ELVN 0.15
- NAVI 0.08
- Stochastic Oscillator
- ELVN 59.11
- NAVI 87.04
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.